Segment Wealth Management LLC increased its position in shares of Pfizer Inc. (NYSE:PFE) by 1.7% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 139,567 shares of the biopharmaceutical company’s stock after purchasing an additional 2,328 shares during the period. Pfizer comprises about 1.2% of Segment Wealth Management LLC’s portfolio, making the stock its 19th largest holding. Segment Wealth Management LLC’s holdings in Pfizer were worth $5,055,000 as of its most recent filing with the SEC.
A number of other hedge funds have also recently bought and sold shares of the stock. Mckinley Capital Management LLC Delaware purchased a new stake in shares of Pfizer in the second quarter worth approximately $103,000. Herndon Capital Management LLC purchased a new stake in shares of Pfizer in the second quarter worth approximately $120,000. Americafirst Capital Management LLC purchased a new stake in shares of Pfizer in the third quarter worth approximately $127,000. Private Vista LLC raised its stake in shares of Pfizer by 2,277.3% in the second quarter. Private Vista LLC now owns 199,317 shares of the biopharmaceutical company’s stock worth $133,000 after purchasing an additional 190,933 shares during the last quarter. Finally, Lipe & Dalton increased its position in shares of Pfizer by 6.9% during the second quarter. Lipe & Dalton now owns 4,626 shares of the biopharmaceutical company’s stock valued at $155,000 after acquiring an additional 300 shares during the last quarter. 71.16% of the stock is currently owned by institutional investors and hedge funds.
In other Pfizer news, Director W Don Cornwell sold 1,758 shares of the stock in a transaction on Tuesday, February 27th. The stock was sold at an average price of $36.79, for a total transaction of $64,676.82. Following the completion of the transaction, the director now directly owns 1,000 shares of the company’s stock, valued at $36,790. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Sally Susman sold 33,368 shares of the stock in a transaction on Tuesday, February 27th. The shares were sold at an average price of $37.03, for a total value of $1,235,617.04. Following the transaction, the executive vice president now directly owns 191,505 shares of the company’s stock, valued at $7,091,430.15. The disclosure for this sale can be found here. Over the last three months, insiders have sold 248,037 shares of company stock valued at $9,064,785. 0.06% of the stock is owned by corporate insiders.
Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share for the quarter, beating the consensus estimate of $0.56 by $0.06. Pfizer had a return on equity of 25.21% and a net margin of 40.55%. The business had revenue of $13.70 billion during the quarter, compared to analyst estimates of $13.67 billion. During the same period in the prior year, the company earned $0.47 earnings per share. Pfizer’s revenue was up .6% compared to the same quarter last year. equities research analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.
Pfizer declared that its board has approved a share buyback program on Monday, December 18th that authorizes the company to repurchase $10.00 billion in shares. This repurchase authorization authorizes the biopharmaceutical company to repurchase shares of its stock through open market purchases. Shares repurchase programs are usually a sign that the company’s board of directors believes its shares are undervalued.
A number of analysts recently commented on the company. Sanford C. Bernstein set a $43.00 price target on Pfizer and gave the company a “buy” rating in a research report on Tuesday, January 30th. Goldman Sachs set a $36.00 price target on Pfizer and gave the company a “neutral” rating in a research report on Tuesday, January 30th. UBS set a $42.00 price target on Pfizer and gave the company a “buy” rating in a research report on Wednesday, January 31st. BMO Capital Markets set a $39.00 price target on Pfizer and gave the company a “buy” rating in a research report on Tuesday, January 30th. Finally, Deutsche Bank set a $38.00 price target on Pfizer and gave the company a “buy” rating in a research report on Wednesday, December 6th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and eleven have given a buy rating to the stock. Pfizer has an average rating of “Hold” and a consensus price target of $39.40.
ILLEGAL ACTIVITY WARNING: “Segment Wealth Management LLC Boosts Position in Pfizer Inc. (PFE)” was originally published by Ticker Report and is the property of of Ticker Report. If you are reading this piece on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this piece can be read at https://www.tickerreport.com/banking-finance/3295969/segment-wealth-management-llc-boosts-position-in-pfizer-inc-pfe.html.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.